Constitutive activation of AKT is identified in up to 70% of acute myeloid leukemia (AML) patients and mediates, at least in part, the leukemogenic effects of activating fms like tyrosine kinase (FLT3) internal tandem duplication (ITD) mutations. Here, AKT1 is linked to acute myeloid leukemia.